Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel for Inoperable Malignant Bowel Obstruction
NCT02365584Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lanreotide in malignant bowel obstruction (MBO), sponsored by Ipsen. Started Jan 2015; status: terminated.
02
Drugs
lanreotide
03
Conditions
malignant bowel obstruction (MBO)
Beyond the preview
Go deeper on NCT02365584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365584.